Trial Profile
A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Elenbecestat (Primary) ; Digoxin; Donepezil; Itraconazole; Rifampicin
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
- 18 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials .gov record
- 31 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials .gov record.